Month: September 2026

MARKHAM, Ontario, Sept. 15, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of September 2026, representing $0.936 per Common Share on an annualized basis.

The dividend will be payable on October 15, 2026 to shareholders of record as at September 30, 2026.

The Company’s dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.

Sienna has a Dividend Reinvestment Plan (the “DRIP”) which allows eligible shareholders of the Company to direct that their cash dividends be reinvested in additional Common Shares. Common Shares issued pursuant to the DRIP are issued from treasury at a 3% discount from the market price. Participation in the DRIP is optional and shareholders who do not wish to participate in the DRIP will continue to receive cash dividends. A complete copy of the DRIP is available under the Investors section of the Company’s website.

About Sienna Senior Living

Sienna Senior Living Inc. (TSX:SIA) offers a full range of senior living options, including independent living, assisted living and memory care under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna’s approximately 15,500 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.

For further information, please contact:
David Hung
Chief Financial Officer & Executive Vice President, Investments
(905) 489-0258
david.hung@siennaliving.ca

PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences:

5th Annual ROTH Healthcare Opportunities Conference
Dates: September 29, 2026
Location: Metropolitan Club, New York, NY
Format: Panel discussion and one-on-one investor meetings
Panel: “The Biotech Reset: Regulatory Uncertainty, Capital Constraints and the Search for Value,” 12:00-12:30 p.m. ET

Investors interested in meeting with PolyPid should contact their ROTH representative directly.

Lytham Partners Fall 2026 Investor Conference
Company Presentation: September 29, 2026 at 12:15 p.m. ET. A replay will be available following the event.
1-on-1 Investor meetings: September 30, 2026
Location: Virtual
Format: Webcast presentation and one-on-one investor meetings.
Webcast registration: https://app.webinar.net/oXx0aBZaQVv.

Investors interested in meeting with PolyPid should contact Lytham Partners at 1×1@lythampartners.com.

Craig-Hallum 17th Annual Alpha Select Conference
Date: November 17, 2026
Location: The Sheraton New York Times Square Hotel, New York, NY
Format: One-on-one investor meetings

Investors interested in meeting with PolyPid should contact their Craig-Hallum representative directly.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

MCLEAN, Va., Sept. 15, 2026 (GLOBE NEWSWIRE) — Worldwide NFT, Inc. (OTC: WNFT) (“WNFT”) (“Company”) announces that the Company has signed a Letter of Intent (“LOI”) to acquire 100% of the capital stock of RedTrace Technologies, Inc. (“RedTrace”), a Maryland-based provider of cybersecurity services to the United States government (www.redtracetech.com). RedTrace generates several million dollars in annual revenue and positive run-rate EBITDA. The LOI is subject to customary closing conditions, including due diligence and execution of definitive documentation, including a formal purchase agreement, and is expected to close in the 4^th calendar quarter of 2026.

“RedTrace is an excellent first acquisition for WNFT,” said Jay Wright, CEO of WNFT. “Kelo Makelele, a decorated former Army Signal Corps officer with experience at U.S. Cyber Command, the National Security Agency, and the FBI, has built a nimble, proven provider of cybersecurity services. RedTrace has a solid reputation with the Army and other government customers. I look forward to working with Kelo as we build a large successful company.”

“We are excited to sign this LOI with WNFT and work with Jay to create a significant force in helping to defend America against cyber threats,” said Kelo Makelele, founder and CEO of RedTrace. “Cyber-attacks are as significant as kinetic threats on the 21^st century battlefield. Having RedTrace become part of a publicly traded company will help give us a larger capability to aid in that fight.”

About RedTrace Technologies, Inc.

RedTrace Technologies, Inc. (RedTrace) is a cyber intelligence-driven cybersecurity, information technology, and information operations firm primarily focused on assisting its commercial, federal, civilian, DoD, and U.S. intelligence community clients to achieve mission success by proactively identifying and mitigating cyber threats; supporting mission-critical IT components; and applying sound business and programmatic management principles – https://www.redtracetech.com/

About Worldwide NFT, Inc.

Worldwide NFT, Inc. (OTC: WNFT; WNFT) is a publicly traded company focused on acquiring strong operating companies, including looking to make accretive acquisitions in the defense, tech, manufacturing, or related industries. -.https://www.wnft.us/.

Cautionary statement on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Words such as “plan,” “goal,” “will,” “look forward,” “would,” “believe,” and “is expected,” and similar language are indicative of forward-looking statements. These forward-looking statements are subject to risks and uncertainties, many of which are outside of the company’s control, that could cause actual results to differ (sometimes materially) from the results expressed or implied in the forward-looking statements, including, among others, the company’s ability to find, finance, and close accretive acquisitions. The RedTrace transaction is subject to customary due diligence and definitive documentation. Therefore revenue and EBITDA numbers are subject to closing the transaction and to maintenance of RedTrace’s existing contracts. Except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Contact: Jay Wright, CEO
Worldwide NFT, Inc.
301.524.4759
jwright@wnft.us

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/48429166-ffeb-477b-a110-0d25f5a3ca43

Synaptics Capacitive Tactile Sensing (CTS) module captures touch data and Astra^® Edge AI processors run inference on device, now supported on NVIDIA Isaac Sim™ and Holoscan.

SAN JOSE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Synaptics^® Incorporated (Nasdaq: SYNA) today announced its first CTS module powered by the SN6012T touch controller is now supported by the open robotics simulation framework, NVIDIA Isaac Sim. The Synaptics CTS module is designed for dexterous robotic hands, grippers, and other Physical AI systems to detect contact and pressure distribution, supporting more precise grip control, object manipulation, and responsive interaction.

The CTS module works effortlessly with Synaptics Astra^® Edge AI processors. These processors serve as a multimodal sensing, inferencing, and connectivity hub unifying touch, vision, motor control, and other sensory signals into synchronized streams to facilitate hierarchical AI systems with support of NVIDIA Holoscan.

As Physical AI platforms increasingly operate in highly dynamic environments and interact directly with humans and objects, developers need simulation environments that capture how contact and force behave at the point of touch. This simulation environment delivers a way to prototype tactile interactions and generate synthetic sensor data. It helps developers expedite validation cycles by enabling perception algorithms before deploying on physical hardware.

The CTS platform is expected to provide:

• An optimized standard tactile module: High 2.5mm pitch taxel density with a 5×12 taxel array, supporting force ranges up to 100N with 0.1N resolution.
• Faster response, low-hysteresis proprietary sensor design: 10x faster rebound response than traditional foam sensors.
• Native Newton engine support: Built from the ground up for NVIDIA’s Newton physics simulation engine.

The Astra AI-native processor platform is designed to:

• Aggregate touch, vision, and motion data into unified streams, delivered to NVIDIA Holoscan over standard Ethernet.
• Offload sensor collection and synchronization from central compute, so robotic platforms can interpret contact, grip, and movement locally.
• Bring localized Edge AI intelligence to humanoids, grippers, and industrial systems, cutting integration complexity.

“Tactile sensing is essential for fast, accurate, and robust robotics and humanoid experiences across all markets,” said Rahul Patel, President and CEO, Synaptics. “Combining Synaptics’ touch modules and Astra Edge AI processors with NVIDIA’s Isaac Sim and Holoscan platform capabilities enables processing of multi-sensory modalities, simplifying integration hurdles and accelerating time-to-market for developers through faster validation cycles.”

“The next generation of Physical AI depends on closing the gap between what robots learn in simulation and how they respond to contact in the real world,” said Deepu Talla, Vice President of Robotics and Edge AI at NVIDIA. “Synaptics is bringing CTS tactile sensing and Astra Edge AI processors to NVIDIA Isaac Sim and Holoscan, helping developers simulate touch and process multimodal sensor data for more precise grip control, object manipulation, and responsive robotic interaction.”

About Synaptics Incorporated

Synaptics (Nasdaq: SYNA) is driving innovation in AI at the Edge, bringing AI closer to end users, and transforming how we engage with intelligent connected devices, whether at home, at work, or on the move. As a go-to partner for forward-thinking product innovators, Synaptics powers the future with its cutting-edge Synaptics Astra^® AI-Native embedded compute, wireless connectivity, and multimodal sensing solutions. We’re making the digital experience smarter, faster, more intuitive, secure, and seamless. From touch, display, and biometrics to AI-driven wireless connectivity, video, vision, audio, speech, and security processing, Synaptics is the force behind the next generation of technology enhancing how we live, work, and play.

Follow Synaptics on LinkedIn, Facebook, Instagram, and YouTube or visit www.synaptics.com.

Synaptics, the Synaptics logo and Astra are trademarks of Synaptics in the United States and/or other countries. All other marks are the property of their respective owners.

Forward-Looking Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities of Synaptics’ CTS module and Astra processors, their integration with NVIDIA Isaac Sim and Holoscan, developer adoption, and market opportunities in robotics and edge AI. These statements involve risks and uncertainties including product development delays, competitive pressures, adoption rates for simulation and edge AI platforms, supply chain constraints, and macroeconomic conditions. For more information on risks, please refer to Synaptics’ most recent Form 10-K and 10-Q filings with the SEC. Synaptics disclaims any obligation to update forward-looking statements except as required by law.

For further information, please contact:
Media Contact
press@synaptics.com

BOSTON, Sept. 15, 2026 (GLOBE NEWSWIRE) — Cabot Corporation (NYSE: CBT) today announced that it has appointed Steve Delahunt, Vice President and Corporate Treasurer, to serve as Chief Financial Officer on an interim basis, effective October 1, 2026. Delahunt will serve in the role while the company continues its search process for a new Chief Financial Officer. 

As previously announced, Erica McLaughlin, currently Executive Vice President, Chief Financial Officer and Head of Corporate Strategy, has been elected President and Chief Executive Officer of Cabot, effective October 1, 2026, succeeding Sean Keohane. McLaughlin will step down from her position as Chief Financial Officer at that time.

“Steve is a highly respected finance leader with deep knowledge of our business, strong relationships across our global organization and a proven track record of disciplined financial leadership,” said Erica McLaughlin, incoming President and Chief Executive Officer. “As we continue executing our strategy and building on our strong financial position, Steve’s experience, judgment and understanding of our business make him exceptionally well suited to lead our finance organization while the Company conducts its search for our next Chief Financial Officer.”

Delahunt has more than 30 years of finance and treasury experience and in the last nine years until January 2026 also led Cabot’s investor relations function. As Corporate Treasurer, he is responsible for the Company’s global treasury activities, capital markets strategy, liquidity management, banking relationships, risk management and pension investment oversight. Over his tenure at Cabot, he has played an integral role in the Company’s capital allocation strategy, financing activities, investor engagement and execution of strategic growth initiatives. As Vice President of investor relations, Delahunt strengthened the Company’s engagement with shareholders and the investment community.

ABOUT CABOT CORPORATION
Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company is a leading provider of reinforcing carbons, specialty carbons, battery materials, engineered elastomer composites, inkjet colorants, masterbatches and conductive compounds, fumed metal oxides and aerogel. For more information on Cabot, please visit the company’s website at cabotcorp.com.

Forward-Looking Statements: This press release contains forward-looking statements. All statements that address expectations or projections about the future, including with respect to the planned leadership transition and expectations for future performance, growth and value creation for stockholders, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, potentially inaccurate assumptions, and other factors, some of which are beyond our control and difficult to predict. If known or unknown risks materialize, or should underlying assumptions prove inaccurate, our actual results could differ materially from past results and from those expressed or implied by forward-looking statements. Important factors that could cause our results to differ materially from those expressed or implied in the forward-looking statements include, but are not limited to: the inherent uncertainty of management transitions and the ability of the Company to successfully execute its planned leadership transition; industry capacity utilization and competition from other specialty chemical companies; safety, health and environmental requirements and related constraints imposed on our business; regulatory and financial risks related to climate change developments; volatility in the price and availability of energy and raw materials; negative or uncertain worldwide or regional economic conditions and market opportunities, including from trade relations, global health matters or geo-political conflicts; failure to achieve growth expectations from new products, applications and technology developments; failure to realize benefits from acquisitions, alliances, or joint ventures or achieve our portfolio management objectives; litigation or legal proceedings; interest rates, tax rates, currency exchange controls, tariffs and fluctuations in foreign currency rates; and other risks and uncertainties described in the reports we file with the Securities and Exchange Commission (“SEC”). These factors are discussed more fully in the reports we file with the SEC, particularly under the heading “Risk Factors” in our annual report on Form 10-K for our fiscal year ended September 30, 2025, which is filed with the SEC and available at www.sec.gov. We assume no obligation to provide revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

Contact:		Vanessa Craigie Corporate Communications vanessa.craigie@cabotcorp.com (617) 342-6015 Robert Rist Investor Relations robert.rist@cabotcorp.com (617) 342-6374

CEO Terry Mendez to participate in panel discussion on federal cannabis reform and what rescheduling means for Colorado operators

DENVER, Sept. 15, 2026 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor (the “Company” or “Safe Harbor”) (NASDAQ: SHFS), a leading fintech platform serving the banking, lending, and financial services needs of the regulated cannabis and hemp industries, announced it will participate in IgniteIt Market Spotlight: Colorado 2026 to address banking access, lending solutions and financial infrastructure for Colorado cannabis operators.

The conference takes place September 18 at the Westin Denver Downtown. Safe Harbor CEO Terry Mendez will join a panel discussion on federal cannabis rescheduling and what ongoing policy reform means for operators in the state. As registration sponsor, Safe Harbor will provide attendee check-in for the event, which is expected to draw more than 300 cannabis operators, investors, lenders and industry partners.

“Operators in mature cannabis markets like Colorado are under increasing pressure to manage capital more efficiently, strengthen their businesses and find financing partners that understand the industry,” said Mendez. “Safe Harbor is focused on providing the banking, capital and broader financial capabilities operators need to build more sustainable businesses.”

Conference Participation Details

• Date: Friday, September 18 – 3:25pm-3:55pm MT
• Panel Title: “The Rescheduling Rundown: What Medical Cannabis Reform Could Mean for Colorado”
• Participants:
  • Terry Mendez, CEO, Safe Harbor Financial
  • Lauren Carboni, Partner, Foley Hoag
  • Nick Richards, Partner + Co-Chair of the cannabis practice group, Greenspoon Marder LLP
  • Tiffany Richardson, Cannabis Managing Partner, Crowe LLP
• Moderated by Ryan Hunter, CRO, Speherex

Colorado is Safe Harbor’s home market. The Company launched its first compliant cannabis banking program in the state in 2015 and has continued to build its platform to help cannabis businesses bank, borrow, operate and grow.

IgniteIt Market Spotlight: Colorado 2026 will bring together cannabis operators, investors and other industry decision-makers to discuss the financial and operational challenges facing the sector, including access to capital and long-term financial sustainability.

If interested in meeting Safe Harbor at the conference, please contact: marketing@shfinancial.org 

About Safe Harbor:
Safe Harbor is a cannabis-exclusive financial platform delivering smarter banking, lending, payments and business services, and institutional solutions tailored to how the cannabis industry actually operates. As one of the original pioneers of compliant financial operations support and cannabis banking consulting in the U.S., Safe Harbor has assisted in the processing of more than $36 billion in cannabis-related depository funds across 41 states and territories. Through its proprietary technology, platform and network of regulated financial institution partners, Safe Harbor empowers cannabis operators to gain clarity, control and confidence in their financial operations. From daily banking and compliance infrastructure to long-term growth, Safe Harbor provides real solutions and personal support, built exclusively for cannabis. Safe Harbor is a financial technology company, not a bank. Banking services are provided by our partner financial institutions. For more information, visit shfinancial.org.

Cautionary Statement Regarding Forward-Looking Statements:
Certain information contained in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included herein may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements may include, but are not limited to, statements with respect to trends in the cannabis industry, including proposed changes in U.S. and state laws, rules, regulations and guidance relating to Safe Harbor’s services; Safe Harbor’s growth prospects and Safe Harbor’s market size; Safe Harbor’s projected financial and operational performance, including relative to its competitors and historical performance; success or viability of new product and service offerings Safe Harbor may introduce in the future; the impact volatility in the capital markets, which may adversely affect the price of Safe Harbor’s securities; the outcome of any legal proceedings that have been or may be brought by or against Safe Harbor; and other statements regarding Safe Harbor’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “outlook,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Safe Harbor’s filings with the U.S. Securities and Exchange Commission. Safe Harbor undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Safe Harbor Investor Relations Contact:
ir@SHFinancial.org

Safe Harbor Media Relations Contact:
safeharbor@kcsa.com

• Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
• Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
• Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of $6.1 million on September 14, 2026, as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical Limited (“Vivasure”) by Haemonetics Corporation (NYSE: HAE, “Haemonetics”). This second payment follows the approximately $5 million upfront payment received in January 2026 and brings total cash proceeds received by Orchestra BioMed from the transaction to approximately $11 million.

Vivasure, an Ireland-based company pioneering next-generation technology for percutaneous vessel closure, had been a strategic holding of Orchestra BioMed since the Company’s formation. Haemonetics completed its acquisition of Vivasure on January 9, 2026, as previously announced.

The payment completes the approximately $11 million in proceeds previously disclosed as expected during 2026. Orchestra BioMed remains eligible to receive up to approximately $10 million in additional proceeds through future revenue earnouts, subject to the achievement of certain milestones, for total potential proceeds of up to $21 million.

Developed by Vivasure, the PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. PerQseal Elite is not available for sale in the United States.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue^® Sirolimus AngioInfusion™ Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

About Haemonetics

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Haemonetics’ innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com

Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com